Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827112 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
A Phase 2 study of Human Immunodeficiency Virus-1, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT00827112: Completed Phase 2 study of Human Immunodeficiency Virus-1, sponsored by ViiV Healthcare.
NCT00827112 is a Phase 2 study of Human Immunodeficiency Virus-1 that has completed, run by ViiV Healthcare. The registered enrollment target is 129 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00827112, a Phase 2 study of Human Immunodeficiency Virus-1, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.
Conditions Studied
Interventions
- DRUG maraviroc
Study Locations (20)
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Orlando
- Pfizer Investigational Site - Pensacola
- Pfizer Investigational Site - St. Petersburg
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Tampa
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
Massachusetts
- Pfizer Investigational Site - Springfield
- Pfizer Investigational Site - Springfield
Connecticut
- Pfizer Investigational Site - Norwalk
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Georgia
- Pfizer Investigational Site - Atlanta
Illinois
- Pfizer Investigational Site - Chicago
Michigan
- Pfizer Investigational Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00827112 record still lists
NCT00827112 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Human Immunodeficiency Virus-1 appearing as the primary indexed condition, and to 1 intervention - of which maraviroc is the first listed.
NCT00827112 names 20 study sites across 9 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00827112 about?
NCT00827112 is a clinical study titled "A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients". This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.
What is the current status of trial NCT00827112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2009-03. Estimated completion is 2011-07.
What conditions does trial NCT00827112 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus-1.
What interventions are being tested in trial NCT00827112?
The interventions under investigation include: maraviroc (DRUG).
Who is sponsoring clinical trial NCT00827112?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00827112 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00827112's enrollment target sits among peer trials
129 553rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia